Related Experiment Video

Updated: Nov 2, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.3K

How I treat pediatric acute myeloid leukemia

Jeffrey E Rubnitz1, Gertjan J L Kaspers2,3

  • 1Department of Oncology, St Jude Children's Research Hospital, Memphis, TN.

Blood
|June 11, 2021
PubMed

Insights

Pediatric acute myeloid leukemia (AML) outcomes trail behind acute lymphoblastic leukemia (ALL) due to disease complexity and limited targeted therapies. Emerging immunotherapies and targeted agents offer new hope for improving treatment results in children with AML.

Area of Science:

  • Pediatric Hematology Oncology
  • Cancer Genomics
  • Immunotherapy

Background:

  • Pediatric acute myeloid leukemia (AML) survival rates lag behind acute lymphoblastic leukemia (ALL).
  • Disease heterogeneity, limited targeted therapies, and slow immunotherapy development contribute to poor AML outcomes.
  • Conventional chemotherapy intensification has reached its limits, necessitating novel therapeutic strategies.

Purpose of the Study:

  • To highlight current challenges in pediatric AML treatment.
  • To discuss emerging targeted therapies and immunotherapies for AML.
  • To illustrate treatment controversies through case studies.

Main Methods:

  • Review of current literature on pediatric AML treatment.
  • Analysis of emerging therapeutic agents including venetoclax, CAR T-cell therapy, antibody therapy, and menin inhibitors.
  • Presentation of four illustrative case studies of pediatric AML.

Main Results:

  • Pediatric AML presents significant challenges due to its heterogeneous nature.
  • New therapeutic avenues like BCL-2 inhibitors, CAR T-cell therapy, and menin inhibitors are showing promise.
  • Case studies reveal ongoing controversies in optimal AML treatment strategies.

Conclusions:

  • Novel targeted therapies and immunotherapies are crucial for advancing pediatric AML treatment.
  • Further research and clinical trials are needed to optimize the use of these new agents.
  • Personalized treatment approaches based on comprehensive genomic analysis are essential for improving outcomes.

More Related Videos

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

122
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

393

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
55
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
601
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.3K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.3K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
48